Loading…
Neuphoria Therapeutics Inc. is projected to decline to $3.92 by 2027, a 0% move from its current price of $3.93. NEUP is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $3.76 | $3.93 | $4.10 | -0.02% |
| Aug 6 | $3.69 | $3.93 | $4.18 | -0.04% |
| Aug 7 | $3.64 | $3.93 | $4.23 | -0.06% |
| Aug 8 | $3.60 | $3.93 | $4.28 | -0.07% |
| Aug 9 | $3.56 | $3.93 | $4.33 | -0.09% |
| Aug 10 | $3.53 | $3.93 | $4.37 | -0.11% |
| Aug 11 | $3.50 | $3.92 | $4.40 | -0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.50 | $3.92 | $4.40 | -0.13% |
| Week 2 | $3.33 | $3.92 | $4.61 | -0.26% |
| Week 3 | $3.21 | $3.91 | $4.78 | -0.39% |
| Week 4 | $3.11 | $3.91 | $4.92 | -0.52% |
| Week 5 | $3.02 | $3.90 | $5.05 | -0.65% |
| Week 6 | $2.94 | $3.90 | $5.17 | -0.78% |
| Week 7 | $2.87 | $3.89 | $5.28 | -0.91% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Neuphoria Therapeutics Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel allosteric ion channel modulators for central nervous system disorders in Australia. Its lead product candidate is BNC210, a selective negative allosteric modulator of the a7 receptor for the treatment of social anxiety disorder, with a phase 2b program to treat post-traumatic stress disorder.
The company also develops BNC101, a monoclonal antibody that targets cancer stem cells and has completed a phase 1 trial; BNC105 for cancer; and NextGen, in preclinical trials for multiple CNS indications. Its Kv3.1/3.2 agonist is in preclinical development to address potential cognitive deficits and negative symptoms in schizophrenia and autism spectrum disorders. Neuphoria also has a collaboration with Merck & Co.
to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with Alzheimer’s disease and other CNS conditions. Formerly known as Bionomics Limited, the company renamed to Neuphoria Therapeutics Inc. in December 2024.
It was incorporated in 1996 and is based in Burlington, Massachusetts.
Neuphoria Therapeutics Inc. trades in the healthcare sector under the ticker NEUP. Its current price is $3.92 with a market capitalization of $21.19M, and it ranks 4581 by market cap.
The stock shows a neutral near-term stance with a 30-day price range and technical levels that define an identifiable channel. The broader forecast suggests meaningful upside over the multi-year horizon, with rising price levels and bullish sentiment emerging in later years. These facts frame a balance between ongoing clinical development risk and potential longer-term value from the company’s pipeline.
A major floor 32.7% below — a decisive break under it would weaken the trend.
The nearest floor, 16.0% below — buyers have tended to step in here.
The nearest ceiling, 16.3% above — a clean break opens room to run.
A major ceiling 39.4% above — clearing it would confirm fresh momentum.
Key NEUP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NEUP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.85 | Buy | $3.83 | Buy |
| MA 10 | $3.68 | Buy | $3.75 | Buy |
| MA 20 | $3.60 | Buy | $3.76 | Buy |
| MA 50 | $4.22 | Sell | $4.06 | Sell |
| MA 100 | $4.49 | Sell | $4.39 | Sell |
| MA 200 | $4.66 | Sell | $5.02 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.51 | Neutral |
| Stoch RSI (14) | 94.88 | Sell |
| CCI (20) | 114.87 | Buy |
| Williams %R (14) | -6.45 | Info |
| MACD (12,26,9) | 0.09 | Buy |
| ROC (12) | 10.23 | Buy |
| Bollinger %B (20,2) | 0.86 | Neutral |
| Stochastic %K (14) | 93.55 | Sell |
| TRIX (15) | -0.68 | Sell |
| Awesome (5,34) | -0.01 | Sell |
| Ultimate (7,14,28) | 64.40 | Neutral |
| Momentum (10) | 0.47 | Buy |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 3.93 | Sell |
| ADX (14) | 20.10 | Buy |
| ATR (14) | 0.13 | Info |
The near-term technical picture is neutral, with RSI14 at 50 indicating balanced momentum between buyers and sellers.
Around the shorter horizon, the stock sits below the SMA50 of $4.24 and the SMA200 of $4.72, which can define resistance and longer-term trend. The 30-day range spans from $2.92 to $5.27, highlighting a wide trading band. Support is identified at $3.30 and resistance at $4.57, outlining the immediate decision points for price movement.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.30 | $3.93 | $4.71 | 0% | Neutral | |
| $2.96 | $3.92 | $5.58 | 0% | Neutral | |
| $2.63 | $3.66 | $5.50 | -7% | Neutral | |
| $3.26 | $4.72 | $7.40 | +20% | Neutral | |
| $3.83 | $5.75 | $9.34 | +46% | Bullish | |
| $3.86 | $5.99 | $10.03 | +52% | Bullish | |
| $3.98 | $6.37 | $10.97 | +62% | Bullish | |
| $3.51 | $5.79 | $10.20 | +47% | Bullish | |
| $3.33 | $5.66 | $10.20 | +44% | Bullish | |
| $3.88 | $6.77 | $12.44 | +72% | Bullish | |
| $4.69 | $9.33 | $18.67 | +137% | Bullish | |
| $9.25 | $20.56 | $46.34 | +423% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.30 | $3.93 | $4.68 | +0.00% |
| September 2026 | $3.26 | $3.92 | $4.89 | -0.26% |
| October 2026 | $3.18 | $3.86 | $4.90 | -1.42% |
| November 2026 | $2.95 | $3.62 | $4.66 | -6.23% |
| December 2026 | $2.92 | $3.62 | $4.71 | -0.16% |
Click any year to see its month-by-month NEUP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Neuphoria Therapeutics Inc.'s 2026 outlook centres on $3.93, within a $3.30 to $4.71 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, NEUP could reach as high as $5.58, with a base case around $3.92 and support toward $2.96 — roughly 0% from $3.93. Price action looks broadly range-bound.
Expect NEUP to range from $2.63 to $5.50 through 2028. The $3.66 average target implies a -7% move from current prices. That is -7% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The NEUP price prediction for 2029 points to an average of $4.72 (low $3.26, high $7.40) — a potential gain of +20% on today's $3.93. Price action looks broadly range-bound.
In 2030, NEUP is projected to trade between $3.83 and $9.34, averaging $5.75 — a potential gain of +46% from today's $3.93. That is up +22% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Neuphoria Therapeutics Inc.'s 2031 outlook centres on $5.99, within a $3.86 to $10.03 range. That is up +4% on the projected 2030 average. That marks a +52% change versus current levels. Momentum favours further upside here.
By 2032, NEUP could reach as high as $10.97, with a base case around $6.37 and support toward $3.98 — roughly +62% from $3.93. Buyers look set to stay in control over this stretch.
Expect NEUP to range from $3.51 to $10.20 through 2033. The $5.79 average target implies a +47% move from current prices. That is -9% versus the projected 2032 average. Momentum favours further upside here.
The NEUP price prediction for 2034 points to an average of $5.66 (low $3.33, high $10.20) — a potential gain of +44% on today's $3.93. Buyers look set to stay in control over this stretch.
In 2035, NEUP is projected to trade between $3.88 and $12.44, averaging $6.77 — a potential gain of +72% from today's $3.93. That is up +20% on the projected 2034 average. Momentum favours further upside here.
Neuphoria Therapeutics Inc.'s 2040 outlook centres on $9.33, within a $4.69 to $18.67 range. That is up +38% on the projected 2035 average. That marks a +137% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, NEUP could reach as high as $46.34, with a base case around $20.56 and support toward $9.25 — roughly +423% from $3.93. Momentum favours further upside here.
Investing $1,000 in NEUP today (≈ 254.452926 NEUP) could be worth
$5,231.43
+$4,231.43 (+423%) by 2050 · US Dollar
Based on the average projected NEUP price of $20.56 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NEUPwould be worth at today's price.
$1,000 invested in NEUP on Jul 31, 2025 (≈ 123.304567 NEUP) would be worth
$484.59
-$515.41 (-51.5%) today · 0.48× · US Dollar
Based on a NEUP entry price of $8.11 vs. today's $3.93.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.64 | $1,079.67 | +8.0% |
| 1 month ago | $3.55 | $1,107.04 | +10.7% |
| 3 months ago | $5.22 | $752.87 | -24.7% |
| 6 months ago | $4.04 | $972.77 | -2.7% |
| 1 year ago | $8.11 | $484.59 | -51.5% |
| All time (4.6y) ago | $176.76 | $22.23 | -97.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NEUP forecast.
Our base-case forecast reaches $7.90 around 2040.
Implied market cap at $7.90: $42.7M
The multi-year forecast shows a bullish trajectory beginning in the later forecast years. In 2029 the avg price is $4.75 with a bullish sentiment and a 21.2% ROI projection. By 2030 the avg is $5.79 with a 47.6% ROI and a bullish outlook, while the 2031–2032 period continues the bullish trend with 2031 avg $5.98, max $10.11, ROI 52.5% and 2032 avg $6.43, max $11.17, ROI 64%.
Looking further out, 2033–2035 remain bullish with 2033 avg $5.76 (max $10.26, ROI 46.9%), 2034 avg $5.60 (max $10.21, ROI 42.9%), and 2035 avg $6.87 (max $12.78, ROI 75.3%). The forecast then accelerates: 2040 avg $9.29, max $18.83, ROI 137% with bullish sentiment, and by 2050 avg $20.87, max $47.75, ROI 432.5% with bullish sentiment. These figures imply substantial long-term upside, but they come with notable variability and risk given the early-stage nature of the company and high near-term volatility (annualized volatility of 90%).
Tap a question to reveal the answer.
In 2030, the forecast shows an avg price of $5.79 with a 47.6% ROI and a bullish sentiment.
The forecast indicates a bullish longer-term outlook with rising averages through 2030–2050 and notable upside, but near-term volatility exists and several years show more modest or flat patterns. Current price is $3.92 with a market cap of $21.19M and a neutral near-term stance.
Yes. The 2031 max forecast is $10.11, and the 2032 max forecast is $11.17, with other years showing values near or above $10, such as 2033 max $10.26 and 2035 max $12.78.
Current price is $3.92 and market cap is $21.19M.
RSI14 is 50 (neutral). The 30-day range is $2.92 to $5.27, with support at $3.30 and resistance at $4.57, indicating a balanced but range-bound near-term setup.
Neuphoria Therapeutics Inc. Community Discussion
0Share your Neuphoria Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.